[Buspirone in the treatment of Generalized Anxiety Disorders].
Małgorzata Rzewuska, K Sobucka
Abstract
Małgorzata Rzewuska, K Sobucka
Abstract
A group of 86 patients, diagnosed with GAD, were treated with doses of 25 mg of Buspirone or 20 mg of Diazepam in a blind study. Comparative efficacy of both drugs and placebo was conducted on 40 patients (archival data). Greater efficacy of Diazepam and Buspirone in states of chronic anxiety was indicated. There were no differences in the intensity of efficacy of both drugs. The effects of Buspirone were equally strong but more general on psychic and somatic anxiety, with the exception of sleep disturbance, in comparison with Diazepam. The efficacy of Buspirone increased after 2 weeks of application. No serious or intensified adverse effects were observed. The incidence of adverse effects was slightly higher in the Buspirone group, and included dizziness, weakness and disturbance of sleep. There were no significant changes in physical examination or laboratory measures.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
A group of 86 patients, diagnosed with GAD, were treated with doses of 25 mg of Buspirone or 20 mg of Diazepam in a blind study. Comparative efficacy of both drugs and placebo was conducted on 40 patients (archival data). Greater efficacy of Diazepam and Buspirone in states of chronic anxiety was indicated. There were no differences in the intensity of efficacy of both drugs. The effects of Buspirone were equally strong but more general on psychic and somatic anxiety, with the exception of sleep disturbance, in comparison with Diazepam. The efficacy of Buspirone increased after 2 weeks of application. No serious or intensified adverse effects were observed. The incidence of adverse effects was slightly higher in the Buspirone group, and included dizziness, weakness and disturbance of sleep. There were no significant changes in physical examination or laboratory measures.
Key concepts: Buspirone, Diazepam, Anxiety, Placebo, Anxiolytic, Medicine, Adverse effect, Anesthesia